9 results about "Estrogen receptor modulator" patented technology

The present disclosure provides compounds that are estrogen receptor modulators (e.g., estrogen receptor agonists, estrogen receptor antagonists, and / or complete estrogen receptor antagonists), and uses thereof.

Tetrahydropyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulating activity or function are described, having the structure of Formula I (see Formula), and pharmaceutically acceptable stereoisomers, tautomers, or salts thereof, with the substituents and structural features described herein. Pharmaceutical compositions and medicinal products comprising the compounds of Formula I are also described, as well as methods of using such estrogen receptor modulators, alone or in combination with other therapeutic agents, to treat diseases or pathological conditions that are mediated by or dependent on estrogen receptors.

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Disclosed is a method for treating of cancer, specifically pancreatic cancer by administering a selective estrogen receptor modulator (SERM), e.g., levormeloxifene, alone or in combination with one or more additional cancer therapies.

The present disclosure provides 2,3,4,9-tetrahydro-lH-pyrido[3,4-b]indole derivatives of formula I as estrogen receptor modulators for the treatment of cancer.

The invention provides an amplified preparation method of a key intermediate of an estrogen receptor modulator, and belongs to the field of medical intermediates. The method comprises the following steps: by taking azetidine-3-one hydrochloride and 3-fluoro-1-halogenated propane as raw materials, reacting in the presence of alkali to obtain an intermediate 1; then carrying out reductive amination reaction on the intermediate 2 and 5-amino-2-methylpyridine to obtain an intermediate 2; reacting with nitrous acid ester in the presence of alkali to obtain an intermediate 3; and finally, reacting in the presence of acid to obtain the 5-((1-(3-fluoropropyl) azetidine-3-yl) amino) pyridinealdehydes. The method is simple and reliable in process and easy for industrial production; the generation amount of an isomer is reduced, and the reaction yield is improved.

This application provides a compound or a pharmaceutically acceptable salt thereof having estrogen receptor modulating activity or function, wherein the compound has the structure of Formula (I) and possesses the substituents and structural features described herein. This application also provides a pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound of Formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating estrogen receptor-related diseases. #imgabs0#

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.